3026 - 3050 of 9156 Results
Title
Year
- Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency2009RESTRICTEDTitle: Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiencyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 15Issue #:Start Page: S42End Page: S45Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1353-8020(09)70778-3Citation Count: 123
-
OPENTitle: Evidence‐based standardized sample handling protocol for accurate blood‐based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization ConsortiumJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 21Issue #: 10Start Page: e70752End Page: e70752Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/alz.70752Best OA location URL: https://doi.org/10.1002/alz.70752Citation Count: 22
-
OPENTitle: Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical ResearchJournal Name: Digital BiomarkersPublisher: S. Karger AGVol: 3Issue #: 3Start Page: 116End Page: 132Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1159/000502951Best OA location URL: https://www.karger.com/Article/Pdf/502951Citation Count: 46
-
OPENTitle: The Michael J. Fox Foundation for Parkinson’s Research Strategy to Advance Therapeutic Development of PINK1 and ParkinJournal Name: BiomoleculesPublisher: MDPI AGVol: 9Issue #: 8Start Page: 296End Page: 296Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/biom9080296Best OA location URL: https://www.mdpi.com/2218-273X/9/8/296/pdfCitation Count: 26
-
OPENTitle: Nilotinib – Differentiating the Hope from the HypeJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 6Issue #: 3Start Page: 519End Page: 522Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-160904Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd160904?id=journal-of-parkinsons-disease%2Fjpd160904Citation Count: 32
-
OPENTitle: Palliative Care and Parkinson's Disease: Time to Move Beyond CancerJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 6Start Page: 1325End Page: 1329Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.28556Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/8217287Citation Count: 24
-
OPENTitle: Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique StudyJournal Name: MDM Policy & PracticePublisher: SAGE PublicationsVol: 6Issue #: 1Start Page: 2381468320978407End Page: 2381468320978407Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/2381468320978407Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/2381468320978407Citation Count: 23
-
OPENTitle: Using Qualitative Methods to Understand Physical Activity and Weight Management Among Bangladeshis in New York City, 2013Journal Name: Preventing Chronic DiseasePublisher: Centers for Disease Control and Prevention - Preventing Chronic DiseaseVol: 13Issue #:Start Page: E87End Page: E87Publication Date:Open Access(OA) Status: OPENLicense: public-domainDOI - Digital Object Identifier: 10.5888/pcd13.160077Best OA location URL: https://www.cdc.gov/pcd/issues/2016/pdf/16_0077.pdfCitation Count: 23
-
OPENTitle: A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson’s Research and CareJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 11Issue #: 3Start Page: 905End Page: 908Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212593Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd212593?id=journal-of-parkinsons-disease%2Fjpd212593Citation Count: 26
-
OPENTitle: Understanding the Lexicon of Fatigue in Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 10Issue #: 3Start Page: 1185End Page: 1193Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3233/jpd-202029Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd202029?id=journal-of-parkinsons-disease%2Fjpd202029Citation Count: 15
-
OPENTitle: The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating FactorsJournal Name: Journal of Patient-Centered Research and ReviewsPublisher: Aurora Health Care, Inc.Vol: 8Issue #: 3Start Page: 232End Page: 238Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.17294/2330-0698.1836Best OA location URL: https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1836&context=jpcrrCitation Count: 18
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial2011RESTRICTEDTitle: AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 10Issue #: 4Start Page: 309End Page: 319Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(11)70039-4Citation Count: 674
- Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial2023RESTRICTEDTitle: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trialJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 114Issue #:Start Page: 105511End Page: 105511Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511Citation Count: 13
-
OPENTitle: Beyond Alzheimer’s disease—translating biomarker insights across CNS diseasesJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 17Issue #: 823Start Page: eadr2511End Page: eadr2511Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.adr2511Best OA location URL: https://pubmed.ncbi.nlm.nih.gov/41191776/Citation Count: 2
- Biomarkers for Parkinson’s Disease2011RESTRICTEDTitle: Biomarkers for Parkinson’s DiseaseJournal Name: Science Translational MedicinePublisher: American Association for the Advancement of Science (AAAS)Vol: 3Issue #: 79Start Page: 79ps14End Page: 79ps14Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1126/scitranslmed.3002488Citation Count: 42
-
OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 41
-
OPENTitle: A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's ResearchJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol:Issue #:Start Page: 1316End Page: 24Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.011940Best OA location URL: https://doi.org/10.1242/dmm.011940Citation Count: 40
-
OPENTitle: The Most Bothersome Aspects of Off Periods Reported by Individuals with Parkinson's DiseaseJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 7Issue #: 3Start Page: 284End Page: 292Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mdc3.12915Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12915Citation Count: 20
-
OPENTitle: Remote Digital Monitoring for Medical Product DevelopmentJournal Name: Clinical and Translational SciencePublisher: WileyVol: 14Issue #: 1Start Page: 94End Page: 101Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1111/cts.12851Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.12851Citation Count: 22
-
OPENTitle: Use of an Online Portal to Facilitate Clinical Trial Recruitment: A Preliminary Analysis of Fox Trial FinderJournal Name: Journal of Parkinson’s DiseasePublisher: SAGE PublicationsVol: 5Issue #: 1Start Page: 55End Page: 66Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-140522Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd140522?id=journal-of-parkinsons-disease%2Fjpd140522Citation Count: 14
-
OPENTitle: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseJournal Name: Journal of Biopharmaceutical StatisticsPublisher: Informa UK LimitedVol: 35Issue #: 5Start Page: 981End Page: 1000Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/10543406.2023.2170400Best OA location URL: https://doi.org/10.1080/10543406.2023.2170400Citation Count: 8
-
OPENTitle: Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s DiseaseJournal Name: MDM Policy & PracticePublisher: SAGE PublicationsVol: 6Issue #: 1Start Page: 23814683211021380End Page: 23814683211021380Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/23814683211021380Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/23814683211021380Citation Count: 14
- Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action2022OPENTitle: Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to ActionJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 4Start Page: 1359End Page: 1363Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-223190Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223190?id=journal-of-parkinsons-disease%2Fjpd223190Citation Count: 15
- Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient2017RESTRICTEDTitle: Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease PatientJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 40Issue #: 5Start Page: 233End Page: 234Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000230Citation Count: 7
-
OPENTitle: Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 5Issue #: 11Start Page: 917End Page: 923Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(06)70579-8Best OA location URL: http://orbilu.uni.lu/handle/10993/17148Citation Count: 82